GO
Loading...

Sanofi SA

More

  • The U.S. drugmaker said it expects earnings, excluding special items, at $2.77 to $2.85 per share in 2014. Analysts, on average, estimated $2.78 per share, according to Thomson Reuters I/B/E/S.

  • US regulators reject Sanofi's MS treatment Lemtrada Monday, 30 Dec 2013 | 7:23 AM ET

    Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.

  • 4 ways to make money off Washington next year Wednesday, 11 Dec 2013 | 7:00 AM ET

    Next year is an election year. There is little chance of a big tax increase, or a government shutdown or debt crisis.

  • Nov 22- The U.S. Food and Drug Administration said on Friday it has approved a vaccine made by GlaxoSmithKline Plc for use in the event of an H5N1 bird flu epidemic. The vaccine, Pandemrix, will be added to the national stockpile and will not be available for commercial use, the FDA said.

  • Midday movers: Apple, Google, Sony & more Thursday, 14 Nov 2013 | 12:47 PM ET

    Some of Thursday's midday movers:

  • SILVER SPRING, Maryland, Nov 13- A federal advisory panel said safety issues do not preclude approval of Sanofi SA's experimental multiple sclerosis drug Lemtrada on Wednesday, but voiced concerns about the quality of clinical studies.

  • SILVER SPRING, Nov 13- A federal advisory panel recommended approval of Sanofi SA's experimental multiple sclerosis drug Lemtrada on Wednesday, but said the drug should be reserved for patients who have failed other therapies. Nathan Fountain of the University of Virginia School of Medicine and the panel's chairperson.

  • SILVER SPRING, Nov 13- A federal advisory panel recommended approval of Sanofi SA's experimental multiple sclerosis drug Lemtrada on Wednesday, but said the drug should be reserved for patients who have failed other therapies. Nathan Fountain of the University of Virginia School of Medicine and the panel's chairperson.

  • SILVER SPRING, Nov 13- Safety problems associated with Sanofi SA's experimental multiple sclerosis drug Lemtrada should not preclude approval of the drug, though it should be restricted to patients who have failed other therapies, an advisory panel to the U.S. Food and Drug Administration said on Wednesday.

  • But use of Merck& Co's widely prescribed Zetia, which is not a statin, and Vytorin, a related drug, will likely not be badly hurt anytime soon, analysts said, because doctors will need time to understand and accept the new guidelines. The Merck drugs have combined annual sales of more than $4 billion, or 10 percent of overall company revenue.

  • Pfizer Inc, Amgen Inc and a partnership of Regeneron Inc and French drugmaker Sanofi SA are racing to develop the new family of medicines called PCSK9 inhibitors. "I read the new guidelines as a negative for any drugs that aren't statins, including PCSK9 inhibitors," said Jon LeCroy, an analyst with MKM Partners.

  • Hide from Fed taper with 3 stocks: Invesco's Sloan Tuesday, 12 Nov 2013 | 3:08 PM ET

    Stay away from consumer-focused companies, Ron Sloan of Invesco says.

  • Nov 5- Keryx Biopharmaceuticals Inc's kidney drug proved effective in treating chronic kidney disease patients not on dialysis, sending the company's shares to a seven-year high on hopes the drug could achieve blockbuster status. "This is great news that opens up the pre-dialysis market for the company," Maxim Group analyst Jason Kolbert told Reuters.

  • Sanofi hit by China slowdown; warns on profit Wednesday, 30 Oct 2013 | 3:17 AM ET

    French drugmaker Sanofi warned on its 2013 profit again as it reported lower-than-expected quarterly results.

  • Achoo! Who’s making money out of flu season Friday, 18 Oct 2013 | 3:28 AM ET

    Concerns that flu could mean an increase in staff sick days has prompted some companies to arrange flu jabs for their employees – boosting sales for some drugs companies.

  • Cramer: 12 things you missed in the market Wednesday, 16 Oct 2013 | 6:03 PM ET

    Has Washington distracted you from these money making developments?

  • Midday movers: Regeneron, Abbott, Sprint & more Wednesday, 16 Oct 2013 | 12:05 PM ET

    Take a look at some of Wednesday's midday movers:

  • After-hours buzz: BBRY, LPX & more Wednesday, 4 Sep 2013 | 5:12 PM ET

    Check out which companies are making headlines after the bell Wednesday:

  • Are drug companies giving up on heart research? Tuesday, 3 Sep 2013 | 12:50 PM ET

    As resources move to other areas, cardiologists fear the battle against heart disease could stall after advances marked by critical drugs to lower cholesterol and blood pressure.

  • Early movers: BIG, CRM, GE, KKD & more Friday, 30 Aug 2013 | 7:55 AM ET

    Some of the names on the move ahead of the open.

Most Popular Video

Thursday, 17 Apr 2014 | 12:00 PM ET

CNBC's Josh Lipton and Allison+Partners Head of Digital Jeremy Rosenberg discuss what Microsoft needs to do to boost Xbox One sales as PS4 sales break the 7 million mark.

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.

Thursday, 17 Apr 2014 | 5:46 PM ET

CNBC voice over talent Jim Birdsall shares the top 5 sayings from traders on "Fast Money" over the years.